U. Demel

Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancer

S. Haas, C. Weidinger, M. Wirth, 2022, The Journal of clinical investigation.

Hyperinflammation in patients with chronic granulomatous disease leads to impairment of hematopoietic stem cell functions.

M. Essers, M. Grez, A. Thrasher, 2016, The Journal of allergy and clinical immunology.

Small-molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapy

M. Wirth, Le Zhang, K. Isaakidis, 2022, Haematologica.

A complex proinflammatory cascade mediates the activation of HSCs upon LPS exposure in vivo

S. Haas, S. Blaszkiewicz, M. Essers, 2022, Blood advances.

SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma

F. Bassermann, S. Müller, M. Wirth, 2022, Blood advances.

Actionable loss of SLF2 drives B‐cell lymphomagenesis and impairs the DNA damage response

F. Bassermann, S. Müller, S. Kossatz, 2023, EMBO molecular medicine.

A prospective observational study of real-world treatment and outcome in secondary CNS lymphoma.

R. Möhle, F. Konietschke, R. Schroers, 2023, European journal of cancer.

Activation of gp130 signaling in T cells drives TH17-mediated multi-organ autoimmunity

S. Ehl, J. Ruland, I. González-Menéndez, 2024, Science Signaling.